+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human plasma solution, Primary antibody: P02430(C1R Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02430(C1R Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The C1R antibody targets the C1r protein, a critical component of the complement system's classical pathway. C1r, a serine protease, forms part of the C1 complex (C1q-C1r-C1s), which initiates immune responses by binding to antigen-antibody complexes or pathogens. Upon activation, C1r undergoes autocatalytic cleavage, converting from a zymogen to an active enzyme, which then activates C1s. This cascade triggers downstream complement pathways, leading to pathogen opsonization, inflammation, and cell lysis.

C1R antibodies are essential tools in studying complement-mediated diseases, autoimmune disorders (e.g., systemic lupus erythematosus), and inflammatory conditions. Dysregulated C1r activity is linked to pathologies like rheumatoid arthritis and age-related macular degeneration. Researchers use C1R antibodies to detect C1r expression, analyze its activation state, or inhibit its proteolytic function in experimental models. Additionally, mutations in the C1R gene are associated with rare genetic disorders, such as periodontal Ehlers-Danlos syndrome, highlighting its role in tissue homeostasis. Therapeutic strategies targeting C1r, including monoclonal antibodies, are under investigation to modulate complement overactivation while preserving immune defense. These antibodies also aid in diagnostic assays for complement deficiencies or hyperactivation, bridging research and clinical applications in immunology.